aluminum hydroxide, magnesium hydroxide, drug combination has been researched along with isoniazid in 1 studies
| Studies (aluminum hydroxide, magnesium hydroxide, drug combination) | Trials (aluminum hydroxide, magnesium hydroxide, drug combination) | Recent Studies (post-2010) (aluminum hydroxide, magnesium hydroxide, drug combination) | Studies (isoniazid) | Trials (isoniazid) | Recent Studies (post-2010) (isoniazid) |
|---|---|---|---|---|---|
| 253 | 100 | 17 | 21,815 | 960 | 4,493 |
| Protein | Taxonomy | aluminum hydroxide, magnesium hydroxide, drug combination (IC50) | isoniazid (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 4.85 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 8.29 | |
| Putative FAD-containing monooxygenase MymA | Mycobacterium tuberculosis H37Rv | 4.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arulselvan, P; El Zowalaty, ME; Fakurazi, S; Geilich, BM; Hussein, MZ; Saifullah, B; Webster, TJ | 1 |
1 other study(ies) available for aluminum hydroxide, magnesium hydroxide, drug combination and isoniazid
| Article | Year |
|---|---|
Development of a biocompatible nanodelivery system for tuberculosis drugs based on isoniazid-Mg/Al layered double hydroxide.
Topics: Aluminum Hydroxide; Animals; Antitubercular Agents; Cell Line; Cell Survival; Drug Combinations; Drug Delivery Systems; Humans; Isoniazid; Magnesium Hydroxide; Mice; Mycobacterium tuberculosis; Nanocomposites; NIH 3T3 Cells | 2014 |